SOPHiA Genetics (NASDAQ: SOPH) announced a multi-year collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop, validate, and deploy two companion diagnostics (CDx) for precision oncology therapies, according to a press release dated Aug. 4, 2026.

Under the agreement, SOPHiA Genetics will develop its Solid Tumor application into a decentralized companion diagnostic. The company will also develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer.

The collaboration is intended to bring SOPHiA Genetics's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies, with the goal of enabling local laboratories to conduct testing at the time of drug approval.

SOPHiA Genetics CEO Ross Muken said in a statement: "A breakthrough therapy only matters to the patients we can find in time to treat. We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch."

SOPHiA Genetics states its cloud-based platform connects more than 1,000 institutions across over 75 countries. The company's companion diagnostic capabilities include clinical trial assay development, regulatory submission in the U.S., EU, Japan, and other markets, and deployment through its SOPHiA DDM platform.